Sight Sciences, INC Form 4 insider transactions

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 12,733 shares of common stock to cover tax liabilities related to vested restricted stock units.

Sight Sciences, Inc. reports that Chief Financial Officer James Rodberg sold 6,902 shares of common stock to cover tax liabilities related to vesting restricted stock units.

David Badawi, Chief Technology Officer and Director at Sight Sciences, Inc., sold 7,418 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Brenton Taylor, EVP of Operations & R&D at Sight Sciences, Inc., sold 2,829 shares of common stock to cover tax liabilities related to vesting RSUs.

Sight Sciences, Inc. reports that Chief Operating Officer Alison Bauerlein sold shares to cover tax liabilities related to vested restricted stock units.

Sight Sciences, Inc. reports that President and CEO Paul Badawi sold 28,684 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Director Staffan Encrantz purchased 14,100 shares of Sight Sciences, Inc. common stock at a weighted average price of $4.879.

Director Tamara Fountain was granted 28,261 restricted stock units as part of the Sight Sciences, Inc. non-employee director compensation program.

Director Staffan Encrantz was granted 28,261 restricted stock units as part of the Sight Sciences non-employee director compensation program.

Director Gerhard Burbach was granted 28,261 restricted stock units as part of the Sight Sciences non-employee director compensation program.

Director Donald Zurbay was granted 28,261 restricted stock units as part of the Sight Sciences non-employee director compensation program.

Director Catherine Mazzacco was granted 28,261 restricted stock units as part of the Sight Sciences, Inc. non-employee director compensation program.

Sight Sciences' Chief Operating Officer, Alison Bauerlein, sold 12,728 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences, Inc. CFO James Rodberg sold shares to cover tax liabilities related to RSU vesting.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold shares to cover tax liabilities related to vested RSUs.

Sight Sciences' Chief Operating Officer, Alison Bauerlein, sold 25,874 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences, Inc. reports that Chief Technology Officer David Badawi sold 8,168 shares of common stock on April 2, 2026, to cover tax liabilities related to vesting restricted stock units.

Brenton Taylor, EVP of Operations & R&D at Sight Sciences, Inc., sold 2,869 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Paul Badawi, President and CEO of Sight Sciences, Inc., reported the sale of 29,244 shares of common stock to cover tax liabilities related to the vesting of restricted stock units.

Sight Sciences' Chief Technology Officer, David Badawi, exercised 21,270 stock options at $0.23 per share, increasing his direct beneficial ownership.

Sight Sciences' Chief Technology Officer, David Badawi, received a grant of 64,915 restricted stock units under the company's 2021 Incentive Award Plan.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, was granted 115,920 restricted stock units valued at $750,000.

Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein was granted 127,512 restricted stock units, vesting quarterly through 2029.

Sight Sciences, Inc. President and CEO Paul Badawi received a grant of 154,560 restricted stock units, vesting quarterly through 2029.

Sight Sciences' Chief Financial Officer, James Rodberg, was granted 86,940 restricted stock units, vesting quarterly through 2029.

Sight Sciences, Inc. granted its EVP of Operations & R&D, Brenton Taylor, 100,464 restricted stock units valued at $650,000.

Sight Sciences' Chief Technology Officer, David Badawi, sold 4,836 shares of common stock on January 16, 2026, at a weighted average price of $6.62 per share to cover tax liabilities from restricted stock unit vesting.

Sight Sciences CFO James Rodberg sold 2,616 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Sight Sciences CEO Paul Badawi sold 22,362 shares of common stock to cover tax liabilities from RSU vesting and corrected previous beneficial ownership reports.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 6,308 shares of common stock at a weighted average price of $6.62 to cover tax liabilities from RSU vesting.